Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: Repeat and replicate

Lay summary Recent evidence confirmed the significant clinical benefit from using immune check point inhibitors, namely PD-1 inhibitors, in patients with advanced cutaneous squamous cell carcinomas. The activity of these different agents seems to be strikingly equivalent. This phase 2 trial confirms a similar clinical benefit to single agent nivolumab in treating this disease. The replication of these findings raises the question of whether substitution of these immunotherapeutic agents can be justified based on smaller confirmatory trials.

Automated summary

Recent evidence confirms the clinical benefit of PD-1 inhibitors in advanced cutaneous squamous cell carcinomas. The activity of different agents appears to be equivalent. The replication of these findings raises the question of substituting immunotherapeutic agents based on smaller trials.